American journal of translational research · 2026
Clinical efficacy and recurrence analysis of endoscopic rubber band ligation combined with external hemorrhoidectomy for mixed hemorrhoids.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Feng Xue, Miao Mi
Аннотация
OBJECTIVE: To evaluate the efficacy and safety of endoscopic rubber band ligation combined with external hemorrhoidectomy (ERBL+EH) for mixed hemorrhoids compared with Milligan-Morgan hemorrhoidectomy (MMH), and to identify risk factors for postoperative recurrence.
METHODS: A retrospective analysis was conducted on 330 patients with stage III-IV mixed hemorrhoids treated between January 2020 and December 2024. Patients underwent either ERBL+EH (n = 185) or MMH (n = 145). Baseline data, perioperative indicators, complications, treatment costs, and 1-year recurrence were assessed. Follow-up was conducted every 3 months. Group differences were analyzed using χ2 or t-tests, and Cox regression was applied to identify independent risk factors for recurrence.
RESULTS: Baseline characteristics were comparable between groups (P > 0.05). ERBL+EH demonstrated significantly better perioperative outcomes, including reduced blood loss, shorter operation and wound healing times, faster pain relief, fewer incisions, and lower postoperative pain scores (all P < 0.05). Complication rates were lower in the ERBL+EH group, particularly anal stenosis, prolapse, incontinence, urinary retention, and incision edema, though postoperative bleeding rates were similar between groups. At 1 year, recurrence was significantly reduced with ERBL+EH (9.7% vs. 31.0%, P < 0.001), with longer time to recurrence (10 vs. 6 months, P = 0.025). Treatment costs were higher in the ERBL+EH group, but length of hospital stay was similar. Clinical efficacy showed a higher rate of marked improvement in the ERBL+EH group (P < 0.001). Multivariate Cox regression identified ERBL+EH as a protective factor against recurrence (HR = 0.218, P = 0.006), while stage IV disease, diabetes, spicy diet, and anal prolapse were independent risk factors.
CONCLUSION: ERBL+EH is superior to MMH in perioperative outcomes, complication control, and recurrence reduction, offering a safe and effective treatment for mixed hemorrhoids, albeit at higher cost. Appropriate patient selection and optimized postoperative management may further enhance long-term outcomes.
METHODS: A retrospective analysis was conducted on 330 patients with stage III-IV mixed hemorrhoids treated between January 2020 and December 2024. Patients underwent either ERBL+EH (n = 185) or MMH (n = 145). Baseline data, perioperative indicators, complications, treatment costs, and 1-year recurrence were assessed. Follow-up was conducted every 3 months. Group differences were analyzed using χ2 or t-tests, and Cox regression was applied to identify independent risk factors for recurrence.
RESULTS: Baseline characteristics were comparable between groups (P > 0.05). ERBL+EH demonstrated significantly better perioperative outcomes, including reduced blood loss, shorter operation and wound healing times, faster pain relief, fewer incisions, and lower postoperative pain scores (all P < 0.05). Complication rates were lower in the ERBL+EH group, particularly anal stenosis, prolapse, incontinence, urinary retention, and incision edema, though postoperative bleeding rates were similar between groups. At 1 year, recurrence was significantly reduced with ERBL+EH (9.7% vs. 31.0%, P < 0.001), with longer time to recurrence (10 vs. 6 months, P = 0.025). Treatment costs were higher in the ERBL+EH group, but length of hospital stay was similar. Clinical efficacy showed a higher rate of marked improvement in the ERBL+EH group (P < 0.001). Multivariate Cox regression identified ERBL+EH as a protective factor against recurrence (HR = 0.218, P = 0.006), while stage IV disease, diabetes, spicy diet, and anal prolapse were independent risk factors.
CONCLUSION: ERBL+EH is superior to MMH in perioperative outcomes, complication control, and recurrence reduction, offering a safe and effective treatment for mixed hemorrhoids, albeit at higher cost. Appropriate patient selection and optimized postoperative management may further enhance long-term outcomes.